Selected research
Industry Research
Nano-antibody CDMO Services Industry Research Report 2026
Market perspective
The global Nano-antibody CDMO Services market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Nano-antibody CDMO Services market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Nano-antibody CDMO Services market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Nano-antibody CDMO Services market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Nano-antibody CDMO Services include Nuoanjian Biotech, BioInno Biotechnology, Sanofi, Medicilon, Bioworkshops, Yaohai Bio, Abace Biotechnology, Shilpa Biologicals Private and ProBio, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Nano-antibody CDMO Services market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Nano-antibody CDMO Services.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Nano-antibody CDMO Services Market by Company
Nuoanjian Biotech
BioInno Biotechnology
Sanofi
Medicilon
Bioworkshops
Yaohai Bio
Abace Biotechnology
Shilpa Biologicals Private
ProBio
PolyPeptide
Pierre Fabre
PeptiFinder Biotech
Jotbody
ImmunoPrecise Antibodies
GenScript
Cultiply
CordenPharma
Bachem
Abzena
53Biologics
Nano-antibody CDMO Services Segment by Type
Vector Construction
Antigen Design
Gene Synthesis
Others
Nano-antibody CDMO Services Segment by Application
Pharmaceutical Companies
Biological Laboratories
Others
Nano-antibody CDMO Services Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nano-antibody CDMO Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nano-antibody CDMO Services and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nano-antibody CDMO Services.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Nano-antibody CDMO Services companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Vector Construction
- Antigen Design
- Gene Synthesis
- Others
Applications
- Pharmaceutical Companies
- Biological Laboratories
- Others
Companies covered
- Nuoanjian Biotech
- BioInno Biotechnology
- Sanofi
- Medicilon
- Bioworkshops
- Yaohai Bio
- Abace Biotechnology
- Shilpa Biologicals Private
- ProBio
- PolyPeptide
- Pierre Fabre
- PeptiFinder Biotech
- Jotbody
- ImmunoPrecise Antibodies
- GenScript
- Cultiply
- CordenPharma
- Bachem
- Abzena
- 53Biologics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Nano-antibody CDMO Services by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Vector Construction
- 2.2.3 Antigen Design
- 2.2.4 Gene Synthesis
- 2.2.5 Others
- 2.3 Nano-antibody CDMO Services by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pharmaceutical Companies
- 2.3.3 Biological Laboratories
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Nano-antibody CDMO Services Breakdown Data by Type
- 3.1 Global Nano-antibody CDMO Services Historic Market Size by Type (2021-2026)
- 3.2 Global Nano-antibody CDMO Services Forecasted Market Size by Type (2027-2032)
4 Nano-antibody CDMO Services Breakdown Data by Application
- 4.1 Global Nano-antibody CDMO Services Historic Market Size by Application (2021-2026)
- 4.2 Global Nano-antibody CDMO Services Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Nano-antibody CDMO Services Market Perspective (2021-2032)
- 5.2 Global Nano-antibody CDMO Services Growth Trends by Region
- 5.2.1 Global Nano-antibody CDMO Services Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Nano-antibody CDMO Services Historic Market Size by Region (2021-2026)
- 5.2.3 Nano-antibody CDMO Services Forecasted Market Size by Region (2027-2032)
- 5.3 Nano-antibody CDMO Services Market Dynamics
- 5.3.1 Nano-antibody CDMO Services Industry Trends
- 5.3.2 Nano-antibody CDMO Services Market Drivers
- 5.3.3 Nano-antibody CDMO Services Market Challenges
- 5.3.4 Nano-antibody CDMO Services Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Nano-antibody CDMO Services Players by Revenue
- 6.1.1 Global Top Nano-antibody CDMO Services Players by Revenue (2021-2026)
- 6.1.2 Global Nano-antibody CDMO Services Revenue Market Share by Players (2021-2026)
- 6.2 Global Nano-antibody CDMO Services Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Nano-antibody CDMO Services Head Office and Area Served
- 6.4 Global Nano-antibody CDMO Services Players, Product Type & Application
- 6.5 Global Nano-antibody CDMO Services Manufacturers Established Date
- 6.6 Global Nano-antibody CDMO Services Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Nano-antibody CDMO Services Market Size (2021-2032)
- 7.2 North America Nano-antibody CDMO Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Nano-antibody CDMO Services Market Size by Country (2021-2026)
- 7.4 North America Nano-antibody CDMO Services Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Nano-antibody CDMO Services Market Size (2021-2032)
- 8.2 Europe Nano-antibody CDMO Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Nano-antibody CDMO Services Market Size by Country (2021-2026)
- 8.4 Europe Nano-antibody CDMO Services Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Nano-antibody CDMO Services Market Size (2021-2032)
- 9.2 Asia-Pacific Nano-antibody CDMO Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Nano-antibody CDMO Services Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Nano-antibody CDMO Services Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Nano-antibody CDMO Services Market Size (2021-2032)
- 10.2 South America Nano-antibody CDMO Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Nano-antibody CDMO Services Market Size by Country (2021-2026)
- 10.4 South America Nano-antibody CDMO Services Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Nano-antibody CDMO Services Market Size (2021-2032)
- 11.2 Middle East & Africa Nano-antibody CDMO Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Nano-antibody CDMO Services Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Nano-antibody CDMO Services Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Nuoanjian Biotech
- 12.1.1 Nuoanjian Biotech Company Information
- 12.1.2 Nuoanjian Biotech Business Overview
- 12.1.3 Nuoanjian Biotech Revenue in Nano-antibody CDMO Services Business (2021-2026)
- 12.1.4 Nuoanjian Biotech Nano-antibody CDMO Services Product Portfolio
- 12.1.5 Nuoanjian Biotech Recent Developments
- 12.2 BioInno Biotechnology
- 12.2.1 BioInno Biotechnology Company Information
- 12.2.2 BioInno Biotechnology Business Overview
- 12.2.3 BioInno Biotechnology Revenue in Nano-antibody CDMO Services Business (2021-2026)
- 12.2.4 BioInno Biotechnology Nano-antibody CDMO Services Product Portfolio
- 12.2.5 BioInno Biotechnology Recent Developments
- 12.3 Sanofi
- 12.3.1 Sanofi Company Information
- 12.3.2 Sanofi Business Overview
- 12.3.3 Sanofi Revenue in Nano-antibody CDMO Services Business (2021-2026)
- 12.3.4 Sanofi Nano-antibody CDMO Services Product Portfolio
- 12.3.5 Sanofi Recent Developments
- 12.4 Medicilon
- 12.4.1 Medicilon Company Information
- 12.4.2 Medicilon Business Overview
- 12.4.3 Medicilon Revenue in Nano-antibody CDMO Services Business (2021-2026)
- 12.4.4 Medicilon Nano-antibody CDMO Services Product Portfolio
- 12.4.5 Medicilon Recent Developments
- 12.5 Bioworkshops
- 12.5.1 Bioworkshops Company Information
- 12.5.2 Bioworkshops Business Overview
- 12.5.3 Bioworkshops Revenue in Nano-antibody CDMO Services Business (2021-2026)
- 12.5.4 Bioworkshops Nano-antibody CDMO Services Product Portfolio
- 12.5.5 Bioworkshops Recent Developments
- 12.6 Yaohai Bio
- 12.6.1 Yaohai Bio Company Information
- 12.6.2 Yaohai Bio Business Overview
- 12.6.3 Yaohai Bio Revenue in Nano-antibody CDMO Services Business (2021-2026)
- 12.6.4 Yaohai Bio Nano-antibody CDMO Services Product Portfolio
- 12.6.5 Yaohai Bio Recent Developments
- 12.7 Abace Biotechnology
- 12.7.1 Abace Biotechnology Company Information
- 12.7.2 Abace Biotechnology Business Overview
- 12.7.3 Abace Biotechnology Revenue in Nano-antibody CDMO Services Business (2021-2026)
- 12.7.4 Abace Biotechnology Nano-antibody CDMO Services Product Portfolio
- 12.7.5 Abace Biotechnology Recent Developments
- 12.8 Shilpa Biologicals Private
- 12.8.1 Shilpa Biologicals Private Company Information
- 12.8.2 Shilpa Biologicals Private Business Overview
- 12.8.3 Shilpa Biologicals Private Revenue in Nano-antibody CDMO Services Business (2021-2026)
- 12.8.4 Shilpa Biologicals Private Nano-antibody CDMO Services Product Portfolio
- 12.8.5 Shilpa Biologicals Private Recent Developments
- 12.9 ProBio
- 12.9.1 ProBio Company Information
- 12.9.2 ProBio Business Overview
- 12.9.3 ProBio Revenue in Nano-antibody CDMO Services Business (2021-2026)
- 12.9.4 ProBio Nano-antibody CDMO Services Product Portfolio
- 12.9.5 ProBio Recent Developments
- 12.10 PolyPeptide
- 12.10.1 PolyPeptide Company Information
- 12.10.2 PolyPeptide Business Overview
- 12.10.3 PolyPeptide Revenue in Nano-antibody CDMO Services Business (2021-2026)
- 12.10.4 PolyPeptide Nano-antibody CDMO Services Product Portfolio
- 12.10.5 PolyPeptide Recent Developments
- 12.11 Pierre Fabre
- 12.11.1 Pierre Fabre Company Information
- 12.11.2 Pierre Fabre Business Overview
- 12.11.3 Pierre Fabre Revenue in Nano-antibody CDMO Services Business (2021-2026)
- 12.11.4 Pierre Fabre Nano-antibody CDMO Services Product Portfolio
- 12.11.5 Pierre Fabre Recent Developments
- 12.12 PeptiFinder Biotech
- 12.12.1 PeptiFinder Biotech Company Information
- 12.12.2 PeptiFinder Biotech Business Overview
- 12.12.3 PeptiFinder Biotech Revenue in Nano-antibody CDMO Services Business (2021-2026)
- 12.12.4 PeptiFinder Biotech Nano-antibody CDMO Services Product Portfolio
- 12.12.5 PeptiFinder Biotech Recent Developments
- 12.13 Jotbody
- 12.13.1 Jotbody Company Information
- 12.13.2 Jotbody Business Overview
- 12.13.3 Jotbody Revenue in Nano-antibody CDMO Services Business (2021-2026)
- 12.13.4 Jotbody Nano-antibody CDMO Services Product Portfolio
- 12.13.5 Jotbody Recent Developments
- 12.14 ImmunoPrecise Antibodies
- 12.14.1 ImmunoPrecise Antibodies Company Information
- 12.14.2 ImmunoPrecise Antibodies Business Overview
- 12.14.3 ImmunoPrecise Antibodies Revenue in Nano-antibody CDMO Services Business (2021-2026)
- 12.14.4 ImmunoPrecise Antibodies Nano-antibody CDMO Services Product Portfolio
- 12.14.5 ImmunoPrecise Antibodies Recent Developments
- 12.15 GenScript
- 12.15.1 GenScript Company Information
- 12.15.2 GenScript Business Overview
- 12.15.3 GenScript Revenue in Nano-antibody CDMO Services Business (2021-2026)
- 12.15.4 GenScript Nano-antibody CDMO Services Product Portfolio
- 12.15.5 GenScript Recent Developments
- 12.16 Cultiply
- 12.16.1 Cultiply Company Information
- 12.16.2 Cultiply Business Overview
- 12.16.3 Cultiply Revenue in Nano-antibody CDMO Services Business (2021-2026)
- 12.16.4 Cultiply Nano-antibody CDMO Services Product Portfolio
- 12.16.5 Cultiply Recent Developments
- 12.17 CordenPharma
- 12.17.1 CordenPharma Company Information
- 12.17.2 CordenPharma Business Overview
- 12.17.3 CordenPharma Revenue in Nano-antibody CDMO Services Business (2021-2026)
- 12.17.4 CordenPharma Nano-antibody CDMO Services Product Portfolio
- 12.17.5 CordenPharma Recent Developments
- 12.18 Bachem
- 12.18.1 Bachem Company Information
- 12.18.2 Bachem Business Overview
- 12.18.3 Bachem Revenue in Nano-antibody CDMO Services Business (2021-2026)
- 12.18.4 Bachem Nano-antibody CDMO Services Product Portfolio
- 12.18.5 Bachem Recent Developments
- 12.19 Abzena
- 12.19.1 Abzena Company Information
- 12.19.2 Abzena Business Overview
- 12.19.3 Abzena Revenue in Nano-antibody CDMO Services Business (2021-2026)
- 12.19.4 Abzena Nano-antibody CDMO Services Product Portfolio
- 12.19.5 Abzena Recent Developments
- 12.20 53Biologics
- 12.20.1 53Biologics Company Information
- 12.20.2 53Biologics Business Overview
- 12.20.3 53Biologics Revenue in Nano-antibody CDMO Services Business (2021-2026)
- 12.20.4 53Biologics Nano-antibody CDMO Services Product Portfolio
- 12.20.5 53Biologics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst